B+
Bull case
25%
Probability
Target price
$4.50
+121.1% vs current
HSCS
HeartSciencesCNasdaq / Health Care Equipment & Services
Last Price
At close
2026-06-03
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$1.20
-41.0% vs current
B-
Bear case
30%
Probability
Target price
$0.35
-82.8% vs current
AI sentiment snapshot
Latest data as of 2026-04-15
Recent news sentiment (30D)
-26.5
Negative
Company
-
Unavailable
Macro
-26.5
Negative
Pulse
-
Unavailable
Sentiment proxy
+34.1
Score
AI commentary
Sentiment remains cautious-to-negative. The primary-source record confirms a real regulatory catalyst, but the stronger near-term fact pattern is balance-sheet stress: the 10-Q says current cash is insufficient for the next twelve months and raises substantial doubt about going concern, while the 8-K only reassures that the COO's passing should not change current commercialization plans [#10-Q-2026-03-16] [#8-K-2026-04-03]. This looks more like a monitoring situation than a high-conviction bullish setup.
RankAlpha Sentiment Codex - 2026-04-15
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-06-30catalystFinancing overhang and dilution risk stays front-and-centerHigh impact
The January 31, 2026 10-Q says existing cash is insufficient to fund the next twelve months, notes substantial doubt about going concern, and shows reliance on the ATM and Streeterville financing; any new raise or more aggressive note-related conversions would likely pressure the stock [#10-Q-2026-03-16].
2026-09-30eventFDA review outcome on MyoVista wavECG 510(k) submissionHigh impact
HeartSciences disclosed that it submitted the MyoVista wavECG device to the FDA on December 15, 2025, and the April 2026 8-K said commercialization plans remain unchanged after the COO's death; a clearance decision is the cleanest upside trigger, but timing remains uncertain [#10-Q-2026-03-16] [#8-K-2026-04-03].
2027-03-31catalystProof of commercial uptake for MyoVista Insights platformHigh impact
The 10-Q says MyoVista Insights launched in mid-2025 and is intended to support clinical workflow while the company continues development and commercialization, but no strong adoption proof is yet disclosed; any credible customer/revenue traction would help de-risk the story over time [#10-Q-2026-03-16].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-15 • Updated nightlySource: Internal modelMethodology